WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018105943) PHARMACEUTICAL COMPOSITION FOR TREATMENT OR ALLEVIATION OF PULMONARY FIBROSIS AND ASTHMA
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/105943    International Application No.:    PCT/KR2017/013799
Publication Date: 14.06.2018 International Filing Date: 29.11.2017
IPC:
A61K 31/4704 (2006.01), A61K 31/4412 (2006.01), A61K 31/404 (2006.01), A61K 45/06 (2006.01)
Applicants: SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION [KR/KR]; 22, Soonchunhyang-ro, Sinchang-myeon, Asan-si, Chungcheongnam-do 31538 (KR)
Inventors: PARK, Choon Sik; (KR)
Agent: PHIL & ONZI INT'L PATENT & LAW FIRM; 3F., 36, Seochojungang-ro, Seocho-gu, Seoul 06643 (KR)
Priority Data:
10-2016-0165761 07.12.2016 KR
10-2016-0165762 07.12.2016 KR
Title (EN) PHARMACEUTICAL COMPOSITION FOR TREATMENT OR ALLEVIATION OF PULMONARY FIBROSIS AND ASTHMA
(FR) COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT OU LE SOULAGEMENT DE LA FIBROSE PULMONAIRE ET DE L'ASTHME
(KO) 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
Abstract: front page image
(EN)The present invention relates to a pharmaceutical composition for treatment of pulmonary fibrosis or neutrophilic asthma or alleviation of symptoms thereof, comprising or using, as active ingredients, laquinimod, paquinimod, and tasquinimod or pharmaceutically acceptable salts thereof, and preferably paquinimod or a pharmaceutically acceptable salt thereof for use in treatment or alleviation of pulmonary fibrosis, and tasquinimod or a pharmaceutically acceptable salt thereof for use in treatment or alleviation of neutrophilic asthma. That is, the present invention relates to a new medicinal use of laquinimod, paquinimod, tasquinimod or pharmaceutically acceptable salts thereof.
(FR)La présente invention concerne une composition pharmaceutique pour le traitement de la fibrose pulmonaire ou de l'asthme neutrophile ou le soulagement de leurs symptômes, comprenant ou utilisant, à titre de principes actifs, du laquinimod, du paquinimod et du tasquinimod ou des sels pharmaceutiquement acceptables de ceux-ci, et de préférence du paquinimod ou un sel pharmaceutiquement acceptable de celui-ci pour une utilisation dans le traitement ou le soulagement de la fibrose pulmonaire, et du tasquinimod ou un sel pharmaceutiquement acceptable de celui-ci pour une utilisation dans le traitement ou le soulagement de l'asthme neutrophile. À savoir, la présente invention concerne une nouvelle utilisation médicale du laquinimod, du paquinimod, du tasquinimod ou des sels pharmaceutiquement acceptables de ceux-ci.
(KO)본 발명은 폐섬유증 또는 호중구성 천식의 치료 또는 이들의 증상의 완화를 위한 약학 조성물에 관한 것으로서, 라퀴니모드, 파퀴니모드, 타스퀴니모드 또는 이들의 약학적으로 허용 가능한 염, 바람직하게는 폐섬유증의 용도로는 파퀴니모드 또는 이의 약학적으로 허용 가능한 염을, 호중구성 천식의 용도로는 타스퀴니모드 또는 이의 약학적으로 허용 가능한 염을 유효 성분으로 포함 또는 이용하는 것을 특징으로 한다. 즉, 본 발명은 라퀴니모드, 파퀴니모드, 타스퀴니모드 또는 이들의 약학적으로 허용 가능한 염의 새로운 의약 용도에 관한 것이다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)